Cytek Biosciences, Inc.

From time to time, we are involved in legal proceedings and claims. See Note 17 to our unaudited interim consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for information regarding the Beckman Coulter Litigation (as defined in Note 17), in which Beckman Coulter, Inc. (“Beckman Coulter”) has asserted patent infringement claims against us.

On October 8, 2026, we filed a complaint with the United States International Trade Commission (the “ITC”) under Section 337 of the Tariff Act of 1930, as amended, against Beckman Coulter and Beckman Coulter Biotechnology (Suzhou) Co., Ltd. The complaint alleges that certain of Beckman Coulter’s spectral flow cytometry products, including its mosaic 88 and mosaic 63 detection modules, infringe U.S. Patent Nos. 12,754,128, 12,487,167 and 10,739,245 owned by us, and seeks a limited exclusion order and cease-and-desist orders barring the importation and sale of the accused products in the United States. As of the date of this filing, the ITC has not yet determined whether to institute an investigation.

On October 16, 2026, we filed a complaint against Beckman Coulter in the United States District Court for the District of Delaware, alleging infringement of U.S. Patent Nos. 12,754,128, 12,487,167, 11,913,868 and 10,739,245 owned by us and seeking damages, including enhanced damages for willful infringement, and preliminary and permanent injunctive relief. We intend to vigorously pursue our claims in both proceedings. The ITC and Delaware proceedings are separate from the Beckman Coulter Litigation, in which Beckman Coulter is the plaintiff and different patents are at issue.